secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0000950170-23-018785
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines Q1 net loss $68.1M, cash $909.8M; guides FY net loss $360-400M
--------------------------------------------------------------------------------

- Net loss of $68.1M for Q1 2023 vs $57.6M loss in Q1 2022; R&D expenses $68.9M (up 22% YoY).
- Cash $909.8M as of March 31, 2023, up from $644.9M in Dec 2022, boosted by $345M public offering in March.
- Updated FY 2023 GAAP net loss guidance to $360-$400M; cash runway projected into 2025.
- Appointed Wei Lin, M.D., as CMO; also hired senior VPs for commercial, regulatory, CMC.
- Clinical progress: RMC-6236 data update mid-2023; RMC-6291 preliminary report H2 2023; RMC-9805 first patient dosing mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000095017023018785/0000950170-23-018785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000095017023018785/rvmd-20230508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-018785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer